Anistreplase: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 18: | Line 18: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
{{ | ==Overview== | ||
'''Anistreplase''' is a [[thrombolytic]] drug.<ref name="pmid8563585">{{cite journal |author=Rawles J |title=Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT) |journal=BMJ |volume=312 |issue=7025 |pages=212–5 |date=January 1996 |pmid=8563585 |pmc=2350007 |doi= 10.1136/bmj.312.7025.212|url=http://bmj.com/cgi/pmidlookup?view=long&pmid=8563585}}</ref><ref name="pmid7612317">{{cite journal |author=Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C |title=Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners |journal=Br J Gen Pract |volume=45 |issue=393 |pages=175–9 |date=April 1995 |pmid=7612317 |pmc=1239197 |doi= |url=}}</ref><ref name="pmid8289038">{{cite journal |author=Rawles J, Light J |title=Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT) |journal=J Epidemiol Community Health |volume=47 |issue=5 |pages=377–381 |date=October 1993 |pmid=8289038 |pmc=1059832 |doi= 10.1136/jech.47.5.377|url=}}</ref> | |||
Anistreplase has been developed by [[Beecham (pharmaceutical company)|Beecham]] as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) | |||
==Mechanism== | |||
It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts [[plasminogen]] to [[plasmin]], which in turn degrades fibrin ([[blood clot]]s) to fibrin split products. | |||
==References== | |||
{{reflist|2}} | |||
{{Antithrombotics}} | {{Antithrombotics}} | ||
[[Category:Drug]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Antithrombotic enzymes]] | |||
Latest revision as of 19:14, 27 July 2014
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C2569H3928N746O781S40 |
| Molar mass | 59042.3 g/mol |
|
WikiDoc Resources for Anistreplase |
|
Articles |
|---|
|
Most recent articles on Anistreplase Most cited articles on Anistreplase |
|
Media |
|
Powerpoint slides on Anistreplase |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Anistreplase at Clinical Trials.gov Clinical Trials on Anistreplase at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Anistreplase
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Anistreplase Discussion groups on Anistreplase Patient Handouts on Anistreplase Directions to Hospitals Treating Anistreplase Risk calculators and risk factors for Anistreplase
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Anistreplase |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Anistreplase is a thrombolytic drug.[1][2][3]
Anistreplase has been developed by Beecham as Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC)
Mechanism
It is a complex of purified human plasminogen and bacterial streptokinase that has been acylated to protect the enzyme's active site. When the drug is administered, the acyl group gets hydrolyzed, thereby freeing the activator complex. It converts plasminogen to plasmin, which in turn degrades fibrin (blood clots) to fibrin split products.
References
- ↑ Rawles J (January 1996). "Magnitude of benefit from earlier thrombolytic treatment in acute myocardial infarction: new evidence from Grampian region early anistreplase trial (GREAT)". BMJ. 312 (7025): 212–5. doi:10.1136/bmj.312.7025.212. PMC 2350007. PMID 8563585.
- ↑ Hannaford P, Vincent R, Ferry S, Hirsch S, Kay C (April 1995). "Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners". Br J Gen Pract. 45 (393): 175–9. PMC 1239197. PMID 7612317.
- ↑ Rawles J, Light J (October 1993). "Loss of quality adjusted days as a trial endpoint: effect of early thrombolytic treatment in suspected myocardial infarction. Grampion Region Early Anistreplase Trial (GREAT)". J Epidemiol Community Health. 47 (5): 377–381. doi:10.1136/jech.47.5.377. PMC 1059832. PMID 8289038.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drug
- Cardiovascular Drugs
- Antithrombotic enzymes